Recent Updates
Recently added Catalysts
NTRA Positive Sentiment

Natera and TransCode Therapeutics to Collaborate on Phase 2a Trial of TTX-MC138 in Colorectal Cancer

Tuesday, October 13, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Natera and TransCode Therapeutics have formed a strategic collaboration to support the enrollment of patients in a Phase 2a trial for TTX-MC138, targeting colorectal cancer. This partnership aims to enhance treatment options for patients with high-risk and advanced cancers. The trial represents a significant step in immuno-oncology and RNA-based therapeutics.

Market Sentiment Analysis

POSITIVE FACTORS

  • Strategic collaboration between Natera and TransCode Therapeutics.
  • Focus on advancing treatment options for colorectal cancer.
  • Phase 2a trial aims to evaluate TTX-MC138's effectiveness.

Full Press Release Details

AUSTIN, Texas, & BOSTON--(BUSINESS WIRE)--Natera, Inc. (Nasdaq: NTRA), a global leader in cell-free DNA and precision medicine, and TransCode Therapeutics, Inc. (Nasdaq: RNAZ), a clinical stage company pioneering immuno-oncology and RNA-based therapeutics for the treatment of high-risk and advanced cancers, today announced a strategic collaboration in colorectal cancer (CRC). The collaboration will support enrollment for TransCode’s Phase 2a trial evaluating TTX-MC138 in patients with CRC. Pati

Frequently Asked Questions

What is the purpose of the collaboration?

The collaboration aims to support patient enrollment in a Phase 2a trial for TTX-MC138 in colorectal cancer.

What type of cancer is TTX-MC138 targeting?

TTX-MC138 is targeting colorectal cancer (CRC) in the Phase 2a trial.

Which companies are involved in the collaboration?

The collaboration involves Natera, Inc. and TransCode Therapeutics, Inc.

What stage is the TTX-MC138 trial currently in?

The trial is currently in Phase 2a.

ShareAdd on Google
Tags: NTRA Natera TransCode Therapeutics TTX-MC138 colorectal cancer clinical trial
Last updated: Oct 13, 2026

Biotech snapshot

Cash runway
$1092M liquidity · $0M/mo burn
Low dilution risk